Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV
June 28, 2019
June 28, 2019
NEW YORK, June 28 -- Pfizer, a pharmaceutical company, issued the following news release:
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved ZIRABEV(TM) (bevacizumab-bvzr), a biosimilar to Avastin(R) (bevacizumab),/1 for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastat . . .
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved ZIRABEV(TM) (bevacizumab-bvzr), a biosimilar to Avastin(R) (bevacizumab),/1 for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastat . . .